Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Viread (TDF) to Vemlidy (TAF) in virologically suppressed chronic hepatitis B
2016-003632-20Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Gilead Sciences. Started Mar 2017; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2016-003632-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003632-20.